Advanced search
Publication Cover
Modern Rheumatology Volume 23, 2013 - Issue 3
Journal homepage
59
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis

Ediz DalkilicDivision of Rheumatology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey;Bademli mah., Egitim cad., Gumuskoy sitesi, 24/20 Mudanya, Bursa, TurkeyCorrespondence[email protected]
,
Mustafa SahbazlarDepartment of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
,
Mustafa GulluluDivision of Nephrology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
,
Mahmut YavuzDivision of Nephrology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
,
Kamil DilekDivision of Nephrology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
,
Alpaslan ErsoyDivision of Nephrology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
,
Guven OzkayaDepartment of Biostatistics, Uludag Medical Faculty, Uludag University, Bursa, Turkey
&
Mustafa YurtkuranDivision of Nephrology, Department of Internal Medicine, Uludag Medical Faculty, Uludag University, Bursa, Turkey
 show all
Pages 525-528 | Received 29 Feb 2012, Accepted 28 May 2012, Published online: 02 Jan 2014

REFERENCES

  • Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312:818–22.
  • Krause D, Schleusser B, Herbom G, Rau R. Response to meth-otrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000;43: 14–21.
  • Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Meth-otrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–7.
  • Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008;58:3675–83.
  • Morgan SL, Baggott JE, Alarcon GS. Methotrexate in rheumatoid arthritis: folate supplementation should always be given. Bio-Drugs. 1997;8:164–75.
  • Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36–43.
  • Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004;34:465–83.
  • Braun J, Rau R. An update on methotrexate. Curr Opin Rheu-matol. 2009;21:216–23.
  • Albrecht K, Muller-Ladner U. Side effects and management of side effects of methotrexate in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:595–101.
  • Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992;35: 138–45.
  • Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int. 1996;15: 195–200.
  • Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a sys-tematic review of the literature. Ann Rheum Dis. 2009;68: 1094–9.
  • Bingham SJ, Buch MH, Lindsay S, Pollard A, White J, Emery P. Parenteral methotrexate should be given before biological ther-apy. Rheumatology (Oxford). 2003;42:1009–10.
  • Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, et al. Comparison of the clinical effcacy and safety of sub-cutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multi-center, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.
  • Whittle SL, Hughes RA. Folate supplementation and metho-trexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–71.
  • Morgan SL, Baggott JE. Folate supplementation during metho-trexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:5102–9.
  • Ujfalussy I, Koo E, Sesztak M, Gergely P. Termination of dis-ease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheuma-tol. 2003;62:155–60.
  • Helfiwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol. 2008;35:472–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.